These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 7051933)
1. Ultrastructural alterations of mycobacterium leprae in skin biopsies of untreated and treated lepromatous patients. Silva MT; Macedo PM; Costa MH; Gonçalves H; Torgal J; David HL Ann Microbiol (Paris); 1982; 133(1):75-92. PubMed ID: 7051933 [TBL] [Abstract][Full Text] [Related]
2. Ultrastructure of Mycobacterium leprae and other acid-fast bacteria as influenced by fixation conditions. Silva MT; Macedo PM Ann Microbiol (Paris); 1982; 133(1):59-73. PubMed ID: 6810742 [TBL] [Abstract][Full Text] [Related]
3. Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy. Bach MA; Wallach D; Flageul B; Hoffenbach A; Cottenot F Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):256-67. PubMed ID: 3522769 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy trial with a triple-drug regimen, including once-monthly Rimactane (Rifampicin), in patients with multibacillary types of leprosy. Reyes-Javier PD; Tantiongco PR Acta Leprol; 1983; 1(3):133-41. PubMed ID: 6359801 [No Abstract] [Full Text] [Related]
5. How much non-infectious are the "non-infectious" lepromatous leprosy patients? Prabhakar MC; Appa Rao AV; Krishna DR; Ramanakar TV Lepr India; 1983 Jul; 55(3):576-83. PubMed ID: 6361383 [TBL] [Abstract][Full Text] [Related]
6. Superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor a clinical trial in lepromatous leprosy of the two regimens of rifampin and dapsone. Gelber RH; Humphres RC; Fieldsteel AH Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):273-83. PubMed ID: 3522770 [TBL] [Abstract][Full Text] [Related]
7. Viability of Myco. leprae in the skin and bone marrow of patients with lepromatous leprosy while on dapsone or lamprene. Karat AB Lepr Rev; 1975 Jun; 46(2 Suppl):69-72. PubMed ID: 1100966 [No Abstract] [Full Text] [Related]
8. [Resistance of Mycobacterium leprae to dapsone and rifampicin: apropos of a survey carried out in the Cape Verde region (Senegal)]. Grosset J; Guelpa-Lauras CC; Millan J; Bodian M; Perani E Med Trop (Mars); 1987; 47(2):171-5. PubMed ID: 3306248 [TBL] [Abstract][Full Text] [Related]
9. [Resistance of Mycobacterium leprae to sulfones (DDS) and rifampicin in recurring lepromatous leprosy in Martinique and Guadeloupe since February 1980]. Guelpa-Lauras CC; Constant-Desportes M; Millan J; Grosset J Acta Leprol; 1982; (86-87):77-80. PubMed ID: 6816000 [No Abstract] [Full Text] [Related]
10. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India. Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978 [TBL] [Abstract][Full Text] [Related]
11. Detection of Mycobacterium leprae and the potential for monitoring antileprosy drug therapy directly from skin biopsies by PCR. Williams DL; Gillis TP; Fiallo P; Job CK; Gelber RH; Hill C; Izumi S Mol Cell Probes; 1992 Oct; 6(5):401-10. PubMed ID: 1474978 [TBL] [Abstract][Full Text] [Related]
12. [New WHO recommendations for the treatment of leprosy]. Acta Leprol; 1997; 10(4):189. PubMed ID: 9527754 [No Abstract] [Full Text] [Related]
13. Combined clofazimine- and dapsone-resistant leprosy. A case report. Kar HK; Bhatia VN; Harikrishnan S Int J Lepr Other Mycobact Dis; 1986 Sep; 54(3):389-91. PubMed ID: 3528345 [TBL] [Abstract][Full Text] [Related]
14. [Sulfone-resistance of Mycobacterium leprae--monotherapy with diaminodiphenylsulfone--the value of triple-drug combinations]. Floch HA Int J Lepr Other Mycobact Dis; 1986 Mar; 54(1):122-5. PubMed ID: 3519797 [TBL] [Abstract][Full Text] [Related]
15. [Histoid leprosy with erythema nodosum leprosum]. Alioua Z; Sbai M; Elhaouri M; Bouzidi A; Boudi O; Ghfir M; Benomar S; Sedrati OL Acta Leprol; 2003; 12(3):107-11. PubMed ID: 15040700 [TBL] [Abstract][Full Text] [Related]
16. Use of NASBA RNA amplification for detection of Mycobacterium leprae in skin biopsies from untreated and treated leprosy patients. van der Vliet GM; Cho SN; Kampirapap K; van Leeuwen J; Schukkink RA; van Gemen B; Das PK; Faber WR; Walsh GP; Klatser PR Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):396-403. PubMed ID: 9030105 [TBL] [Abstract][Full Text] [Related]
17. Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study. Ebenezer GJ; Job A; Abraham S; Arunthathi S; Rao PS; Job CK Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):292-7. PubMed ID: 10575409 [TBL] [Abstract][Full Text] [Related]
18. Effect of dapsone in eliminating M. leprae from the skin of lepromatous patients, a study of 609 cases. Koticha KK; Sane AB Int J Lepr Other Mycobact Dis; 1971; 39(4):829-37. PubMed ID: 4949310 [No Abstract] [Full Text] [Related]
19. A statistical analysis of two chemotherapy trials in lepromatous leprosy. II. Interactions among patient variables. Am J Trop Med Hyg; 1978 Sep; 27(5):1015-8. PubMed ID: 362951 [TBL] [Abstract][Full Text] [Related]
20. Results of a modified WHO regimen in highly bacilliferous BL/LL patients. Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa ; Sharma VD; Shivannavar CT; Katoch VM Int J Lepr Other Mycobact Dis; 1989 Jun; 57(2):451-7. PubMed ID: 2664042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]